ole of inflammation and antiinflammation therapies in keratoconjunctivitis sicca Original Research (4893) Total Article Views Authors: Koray Gumus, Dwight H Cavanagh Published Date October 2008 Volume 2009:3 Pages 57 - 67 DOI: http://dx.doi.org/10.2147/OPTH.S3023 Koray Gumus1, Dwight H Cavanagh2 1Department of Ophthalmology, Erciyes University School of Medicine, Kayseri, Turkey; 2Department of Ophthalmology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA Purpose: To review and integrate recent advances in identifying the role of inflammation in the pathogenesis of dry eye conditions and the biological rationale and practical clinical aspects of newer, antiinflammatory theories. Methods: A comprehensive literature survey. Results and conclusion: Keratoconjunctivitis Sicca (KCS) is a multifactorial and complex disorder in which ocular surface infl ammations play a central role. Identification of specific CD4-T-Cell pathways and the recent recognition of targeting of alpha-fodrin suggest a case for novel new therapeutic aspects such as anti-CD4 monoclonal antibodies, systemic linoleic and gamma-linolenic acids, and omega-6 essential fatty acids. Replacement of tear volume with nonpreserved wetting agents and standard typical antiinflammatory corticosteroid and/or cyclosporine A continues to be central current conventional therapy for KCS.